Brandao, Mariana ORCID: 0000-0002-1653-3544, Maurer, Christian, Ziegelmann, Patricia Klarmann, Ponde, Noam F., Ferreira, Arlindo ORCID: 0000-0002-1567-9322, Martel, Samuel, Piccart, Martine, de Azambuja, Evandro ORCID: 0000-0001-9501-4509, Debiasi, Marcio and Lambertini, Matteo ORCID: 0000-0003-1797-5296 (2020). Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open, 5 (4). LONDON: BMJ PUBLISHING GROUP. ISSN 2059-7029

Full text not available from this repository.

Abstract

Background Several endocrine therapy (ET)-based treatments are available for patients with advanced breast cancer. We assessed the efficacy of different ET-based treatments in patients with hormone receptor-positive/HER2-negative advanced breast cancer with endocrine-sensitive or endocrine-resistant disease. Methods We searched Medline and Cochrane Central Register of Controlled Trials up to 15 October 2019 and abstracts from major conferences from 2016 to October 2019. We included phase II/III randomised trials, comparing >= 2 ET-based treatments. Progression-free survival (PFS) and overall survival (OS) were analysed by network meta-analyses using MTC Bayesian models based on both fixed-effect and random-effect models; relative treatment effects were measured as HRs and 95% credibility intervals (CrI). All statistical tests were two-sided. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed and this systematic review is registered in the PROSPERO database. Results 55 publications reporting on 32 trials (n=12 293 patients) were included. Regarding PFS in the endocrine sensitive setting (n=5200; 12 trials), the combination of cyclin-dependent kinases (CDK)4/6-inhibitors (CDK4/6i)+fulvestrant 500 mg (F500) was likely the most effective treatment (surface under the cumulative ranking curve (SUCRA)=97.3%), followed by CDK4/6i+aromatase inhibitor +/- goserelin; there was no significant difference between them (HR 0.82; 95% CrI 0.54-1.25). Regarding OS (n=2157; five trials), the most effective treatment was probably CDK4/6i+F500 (SUCRA=97.3%); comparing CDK4/6i+F500 versus F500 held a HR of 0.77 (95% CrI 0.63-0.95). Regarding PFS in the endocrine-resistant setting (n=6635; 20 trials), CDK4/6i+F500 was likely the most effective treatment (SUCRA=95.7%), followed by capivasertib+F500, without significant difference between them (HR 0.91; 95% CrI 0.60-1.36). For OS (n=4377; 11 trials), the most effective treatments were capivasertib+F500 (SUCRA=84.7%) and CDK4/6i+F500 (SUCRA=69.9%). Comparing CDK4/6i+F500 versus F500 held a HR of 0.77 (95% CrI 0.67-0.89). Conclusions CDK4/6i+F500 is likely the best treatment option in both endocrine-sensitive and endocrine-resistant diseases for PFS, and in endocrine-sensitive patients for OS. Concerning OS in endocrine-resistant patients, capivasertib+F500 and CDK4/6i+F500 are likely the best treatments. PROSPERO registration number CRD42018104628.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Brandao, MarianaUNSPECIFIEDorcid.org/0000-0002-1653-3544UNSPECIFIED
Maurer, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ziegelmann, Patricia KlarmannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ponde, Noam F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ferreira, ArlindoUNSPECIFIEDorcid.org/0000-0002-1567-9322UNSPECIFIED
Martel, SamuelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Piccart, MartineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Azambuja, EvandroUNSPECIFIEDorcid.org/0000-0001-9501-4509UNSPECIFIED
Debiasi, MarcioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lambertini, MatteoUNSPECIFIEDorcid.org/0000-0003-1797-5296UNSPECIFIED
URN: urn:nbn:de:hbz:38-327267
DOI: 10.1136/esmoopen-2020-000842
Journal or Publication Title: ESMO Open
Volume: 5
Number: 4
Date: 2020
Publisher: BMJ PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 2059-7029
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
EVEROLIMUS PLUS EXEMESTANE; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; PROGRESSION-FREE SURVIVAL; FULVESTRANT 500 MG; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITORS; 1ST-LINE TREATMENT; AMERICAN SOCIETYMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/32726

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item